Health Catalyst (HCAT) Scheduled to Post Quarterly Earnings on Thursday

Health Catalyst (NASDAQ:HCAT) will issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of $0.03 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. Health Catalyst had a negative net margin of 39.92% and a negative return on equity of 12.19%. The firm had revenue of $75.08 million for the quarter, compared to analyst estimates of $73.67 million. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT opened at $6.95 on Tuesday. The business has a 50-day moving average price of $7.11 and a 200-day moving average price of $8.17. Health Catalyst has a 52-week low of $5.45 and a 52-week high of $14.37. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.42 and a current ratio of 4.42.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on HCAT shares. Evercore ISI reduced their price objective on Health Catalyst from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, February 23rd. KeyCorp restated a “sector weight” rating on shares of Health Catalyst in a research report on Wednesday, April 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Wednesday, April 10th. Piper Sandler reissued an “overweight” rating and set a $15.00 price target (down from $17.00) on shares of Health Catalyst in a report on Friday, February 23rd. Finally, Guggenheim upgraded shares of Health Catalyst from a “neutral” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Friday, January 26th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $12.10.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.